These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Letter: Alleviation of IUD menorrhagia with ethamsylate.
    Author: Harrison RF, Campbell S.
    Journal: Br Med J; 1976 Mar 13; 1(6010):649-50. PubMed ID: 766907.
    Abstract:
    When menorrhagia is associated with an IUD it may be best to advise continuation of the method and prescribe a therapy that can minimize men strual distrubance. Ethamsylate, which has been useful in primary menor rhagia, is undergoing evaluation. It appears to combat excessive menstr ual flow by it hemostatic properties of increasing capillary resistance and reducing bleeding time. In a preliminary study of 13 patients compl aining of menorrhagia associated with IUDs in situ for at least 1 year, menstrual blood loss was estimated based on the iron content of soiled sanitary wear. 500 mg 4 times daily from 5 days before the anticipated onset of menstruation for 10 days was administered. Mean blood loss was 64.8 ml before treatment and 64.6 ml during placebo therapy (p less than .1) but was significantly less (53.5 ml; p less than .05) during ethamsy late therapy. These results suggest that a patient with an IUD in situ who complains of menorrhagia should be treated with ethamsylate.
    [Abstract] [Full Text] [Related] [New Search]